Quick answer
After HIFU or another focal therapy, recurrence is confirmed by biopsy. PSA does not drop to zero, because part of the prostate is still there, and there is no single definition of failure like the Phoenix criterion used after radiotherapy.4,5 MRI points to the suspicious area, the biopsy confirms it, and PSMA PET can look for disease outside the prostate.4,8,10 The options are repeat focal therapy, salvage radical prostatectomy, radiotherapy and, in selected cases, surveillance. The American guideline recommends offering whole-gland treatment.3 Surgery after focal therapy has more positive margins than surgery as the first treatment.1
What failure after focal therapy means
Focal therapy treats only the tumor area and leaves the rest of the gland in place. That is why cancer can come back in two places:7
- Inside the treated area: the tumor was not completely destroyed.
- Outside the treated area: a focus that was already there and did not show up on the tests, or a new focus, in the part of the prostate that was not treated.
In a review cited by the European guideline, after one year, 8.8% of men had ISUP grade 2 or higher cancer in the treated area and 13% anywhere in the prostate.1 In an American registry of 101 men treated with cryotherapy, HIFU or electroporation, 17.8% had a biopsy-confirmed recurrence in a little over a year of follow-up: 7 inside the treated area, 9 outside it and 2 in both places.7
In the studies cited here, failure on biopsy means finding ISUP grade 2 or higher cancer (Gleason 3 + 4 or more) after treatment.6,7 The page on Gleason and ISUP explains these grades.
PSA after focal therapy
After prostatectomy, PSA falls to almost zero. After focal therapy, it falls but is still produced by the untreated part of the prostate. A consensus of 65 experts considers PSA an unreliable marker of failure, although it recommends measuring it every 3 months in the first year and every 6 months after that.4
There is no accepted definition for focal therapy like the Phoenix criterion. The Phoenix criterion (a rise of 2 ng/mL above the lowest value) was created for radiotherapy, which treats the whole gland.5 The page PSA rising after radiotherapy explains that other situation.
What exists are proposals:
- English registry of focal HIFU (598 men): a PSA 1 ng/mL above the lowest value at 12 months, or 1.5 ng/mL above it at 24 and 36 months, did well at identifying men who needed MRI and biopsy. The authors call for validation in other studies.6
- American registry (101 men): 67% of biopsy-confirmed recurrences happened without PSA meeting the Phoenix criterion.7
In practice, a rising PSA is a warning sign that leads to more tests. On its own, it neither confirms nor rules out recurrence.4,7
MRI after focal therapy
MRI is the preferred imaging test during follow-up. The 65-expert consensus proposes doing it at 6 and 18 months.4 It is read differently from the MRI of someone who has never been treated, because the treated area changes in appearance.
- TARGET consensus (2024): 23 experts from Europe and North America recommend routine MRI at 12 months and not using the PI-RADS score inside the treated area. They propose a 5-point scale of their own, in which focal, nodular, early contrast enhancement is the most suspicious finding.8
- PI-FAB score (2023): another proposed scoring system for MRI after ablation. The authors point out that the MRI from before treatment needs to be available for comparison.9
MRI does not see everything. In 35 men who had surgery after focal HIFU, it had shown 81.8% of recurrences inside the treated area and 60.7% of those outside it.13 In the American registry, half of the biopsy-confirmed recurrences had nothing suspicious on MRI.7 The page on MRI and PI-RADS explains the test.
Biopsy: targeted and systematic
The biopsy is what confirms recurrence. The 65-expert consensus recommends, 6 to 12 months after treatment, a targeted biopsy of the treated area together with a systematic biopsy of the rest of the prostate.4 The American guideline asks for a biopsy before any local salvage treatment.3
The authors of the American registry concluded that, since many recurrences appear without a PSA rise and without MRI changes, biopsy remains essential during follow-up.7 The pages on fusion biopsy and transperineal biopsy explain how it is done.
PSMA PET
Before treating again, it is important to know whether the cancer is confined to the prostate. PSMA PET has become the first-line imaging test for restaging recurrent prostate cancer, but data after focal therapy are still limited.10
- 2026 study (112 men): after HIFU, laser or cryotherapy, with suspected recurrence, PSMA PET showed cancer inside the prostate in 82%, in pelvic lymph nodes in 15% and at distant sites in 9%. In a subgroup of 39 men with MRI and biopsy, it detected 85% of cases, compared with 82% for MRI. It is a single-center, retrospective study.10
- European guideline: says it has not yet been adequately evaluated whether tests such as PSMA PET add to MRI in this setting.1
In the largest series of prostatectomies after focal therapy, disease outside the prostate was ruled out before surgery with pelvic MRI, a bone scan or PET.12
Treatment options
For men being treated again after focal therapy, the American guideline recommends offering whole-gland treatment, with prostatectomy or radiotherapy, because prostate cancer is often multifocal (expert opinion).3 In the studies, all four options appear:
| Option | What it is | What the studies show |
|---|---|---|
| Repeat focal therapy | Repeating the ablation in the area that failed or in a new focus | In the English registry, 252 of 1,379 men had repeat focal HIFU11; registry data suggest repeat HIFU does not significantly worsen urinary or erectile function1 |
| Salvage radical prostatectomy | Removing the whole prostate and the seminal vesicles | More positive margins than primary surgery; continence at one year of 83% in the largest series1,12 |
| Radiotherapy | Irradiating the whole prostate | About 20% PSA recurrence and few side effects, in the review cited by the European guideline1 |
| Surveillance | Follow-up with PSA, MRI and biopsy | In the American registry, 3 of the 18 men with recurrence went on surveillance7 |
In the American registry, among the 18 men with recurrence, 55.6% had repeat focal therapy, 16.7% went on surveillance, 11.1% had surgery, 11.1% had radiotherapy and 5.6% had whole-gland ablation. Recurrences were usually small.7 In the English HIFU registry, 92 men needed whole-gland treatment.11
Salvage prostatectomy: what the studies show
Radical prostatectomy after focal therapy is done on a prostate that has already been treated. The studies show what changes compared with surgery as the first treatment:
| Study | Who | Result |
|---|---|---|
| Review cited by the EAU | 482 patients operated on after focal therapy | Positive margins in 27%, slightly more urine leakage and more early complications, most managed without further surgery1 |
| Marconi, 2019 | 82 men, robotic surgery, several centers | No intraoperative complications and no major complications afterwards; 83% continent at one year; 74%, 48% and 36% progression-free at 12, 24 and 36 months12 |
| Thompson, 2019 | 35 men operated on after focal HIFU | Positive margins in 40%, 84.6% of them in the treated region; 82.4% had more advanced cancer in the specimen than expected13 |
| Ambrosini, 2024 | 68 operated on after focal therapy, matched with 203 primary surgeries | Free of PSA recurrence at 2 years in 72.4% and 76.0%; similar operating time, blood loss, catheter time and continence at one year14 |
| Spitznagel, 2021 | 13 operated on after focal HIFU, matched with 26 | More complications requiring a procedure (4 of 13 vs. 2 of 26), mostly drain placement; similar urinary and erectile function at one year15 |
Three points help read these numbers:
- Where the cancer came back matters. In the series of 82 men, recurrence inside the treated area and tumor in the seminal vesicles (pT3b) were the factors linked to further recurrence. The authors suggest that recurrence inside the treated area tends to be a more aggressive cancer.12
- Surgeon experience was part of the matched analysis. All operations were done by surgeons with 500 or more cases, and the authors tie the similarity with primary surgery to that setting.14
- Salvage after focal therapy differs from salvage after radiotherapy. In a study of 439 robotic salvage prostatectomies, men who had radiotherapy arrived with less favorable cancer than men who had focal therapy, and complications were similar in both groups.17
Positive surgical margins, continence and PSA after prostatectomy have their own pages.
Salvage surgery or radiotherapy
No randomized trial has compared the two after focal therapy. The most cited comparison comes from an English center, with 100 robotic salvage prostatectomies and 100 salvage radiotherapy courses after HIFU, cryotherapy or electroporation:16
- PSA control: in intermediate risk, similar in both groups (90.0% with radiotherapy and 75.6% with surgery at 3 years). In high risk, better with radiotherapy (86.3% and 66.0%). The surgery group had more high-risk men and shorter follow-up.
- Pad-free continence: no difference, with 77.2% and 84.7% after surgery at 12 and 24 months, and 75.0% and 74.0% after radiotherapy.
- Erections: better preserved with radiotherapy.
- Radiotherapy side effects: severe bowel effects in 4% and urinary effects in 5%.
The choice between the two depends on each case and is discussed with the patient. The page surgery or radiotherapy compares the two treatments in general.
What the guidelines say
| Topic | European guideline (2026) | American guidelines (AUA) |
|---|---|---|
| Focal therapy as first treatment | For intermediate risk, only within clinical trials or registries (strong recommendation); not to be offered for high risk | Still investigational |
| Follow-up | No well-defined pathway yet; the role of MRI and PSA is still being studied | PSA, MRI and biopsy, tailored to each patient |
| Before salvage | The role of PSMA PET alongside MRI has not been adequately evaluated | Biopsy before any local salvage treatment |
| Salvage treatment | Cites the surgery review (27% positive margins) and the radiotherapy review (about 20% PSA recurrence) | Offer whole-gland treatment, with surgery or radiotherapy (expert opinion) |
Sources: European guideline,1 American localized prostate cancer guideline2 and American salvage guideline.3 The pages on HIFU and cryotherapy explain each technique and what the studies show when it is the first treatment.
Second opinion
Men who have had focal therapy and seen their PSA rise, or received a positive follow-up biopsy, usually come with many questions: whether the cancer really came back, where it is and what paths are open now. A second opinion can be done entirely online, in English, with your test results sent in advance. We go through the MRI from before and after treatment, the biopsy and what the guidelines say for your case.
Send your case
If you have had HIFU or another focal therapy and have a rising PSA, a new MRI or a positive biopsy, and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
How do I know if the cancer came back after focal therapy?+
Through a biopsy. PSA does not drop to zero after focal therapy, because part of the prostate is still there, and a consensus of 65 experts considers PSA an unreliable marker of failure.4 MRI helps point to the suspicious area, and the biopsy confirms it.4,8 In an American registry, half of the recurrences were not visible on MRI, and 67% happened without PSA meeting the Phoenix criterion.7
Is there a PSA definition of failure after focal therapy, like the Phoenix criterion?+
There is no single accepted definition. The Phoenix criterion (a rise of 2 ng/mL above the lowest value) was created for radiotherapy.5 In an English registry of focal HIFU, a PSA 1 ng/mL above the lowest value at 12 months, or 1.5 ng/mL at 24 to 36 months, helped identify men who needed MRI and biopsy, but the authors call for validation.6
Can MRI see cancer that has come back?+
Often, but not always. In a series of men who had surgery after focal HIFU, MRI had shown 81.8% of the recurrences inside the treated area and 60.7% of those outside it.13 An international consensus recommends not using the PI-RADS score inside the treated area and proposes its own scale; focal, nodular, early contrast enhancement is the most suspicious finding.8
Does PSMA PET help after focal therapy?+
It may, but data are still limited. In a study of 112 men with suspected recurrence, PSMA PET showed cancer inside the prostate in 82%, in pelvic lymph nodes in 15% and at distant sites in 9%.10 The European guideline says the role of PSMA PET in this setting has not yet been adequately evaluated.1
What are the options when focal therapy fails?+
Repeat focal therapy, salvage radical prostatectomy, radiotherapy or, in selected cases, surveillance. The American guideline recommends offering whole-gland treatment, with surgery or radiotherapy (expert opinion).3 In the English HIFU registry, 252 of 1,379 men had repeat focal treatment and 92 had whole-gland treatment.11
Is prostatectomy after focal therapy more difficult?+
Studies show more positive margins than when surgery is the first treatment. In a review of 482 patients cited by the European guideline, the positive margin rate was 27%, with slightly more urine leakage and more early complications, most managed without further surgery.1 In centers with experienced surgeons, a matched analysis found results similar to primary surgery.14
Is surgery or radiotherapy better after focal therapy?+
There is no randomized trial. In an English center with 100 surgeries and 100 radiotherapy courses after ablation, PSA control was similar in intermediate risk and better with radiotherapy in high risk; pad-free continence was similar, and erections were better preserved with radiotherapy.16 The choice depends on each case and is discussed with the patient.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
- Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024;211(4):526-532. PubMed
- Lebastchi AH, George AK, Polascik TJ, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol. 2020;78(3):371-378. PubMed
- Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974. PubMed
- Huber PM, Afzal N, Arya M, et al. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol. 2020;203(4):734-742. PubMed
- Tremblay S, Tabei SS, Tayebi S, et al. Pathologic failure and salvage approaches following focal therapy for localized prostate cancer. Can J Urol. 2026;33(4):799-810. PubMed
- Light A, Mayor N, Cullen E, et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol. 2024;85(5):466-482. PubMed
- Giganti F, Dickinson L, Orczyk C, et al. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6(6):629-634. PubMed
- Jafarvand M, Farolfi A, Mei R, et al. PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study. J Nucl Med. 2026;67(11):1748-1754. PubMed
- Reddy D, Peters M, Shah TT, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol. 2022;81(4):407-413. PubMed
- Marconi L, Stonier T, Tourinho-Barbosa R, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol. 2019;76(1):27-30. PubMed
- Thompson JE, Sridhar AN, Tan WS, et al. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol. 2019;201(6):1134-1143. PubMed
- Ambrosini F, Hagemann J, Pose R, et al. Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: a matched-pair analysis. World J Urol. 2024;43(1):7. PubMed
- Spitznagel T, Hardenberg JV, Schmid FA, et al. Salvage Robotic-assisted Laparoscopic Radical Prostatectomy Following Focal High-Intensity Focused Ultrasound for ISUP 2/3 Cancer. Urology. 2021;156:147-153. PubMed
- Nathan A, Ng A, Mitra A, et al. Comparative Effectiveness Analyses of Salvage Prostatectomy and Salvage Radiotherapy Outcomes Following Focal or Whole-Gland Ablative Therapy (High-Intensity Focused Ultrasound, Cryotherapy or Electroporation) for Localised Prostate Cancer. Clin Oncol (R Coll Radiol). 2022;34(1):e69-e78. PubMed
- Wenzel M, Nathan A, Covas Moschovas M, et al. Oncological Outcomes After Robotic Salvage Radical Prostatectomy in Patients Primarily Treated With Focal Versus Radiation Therapy: A Junior ERUS/YAU Collaborative Study. Prostate. 2025;85(14):1332-1341. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
